Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
- PMID: 12775615
- PMCID: PMC156459
- DOI: 10.1136/bmj.326.7400.1171
Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
Abstract
Objectives: To investigate the relative impact on publication bias caused by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies.
Design: 42 placebo controlled studies of five selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority as a basis for marketing approval for treating major depression were compared with the studies actually published (between 1983 and 1999).
Results: Multiple publication: 21 studies contributed to at least two publications each, and three studies contributed to five publications. Selective publication: studies showing significant effects of drug were published as stand alone publications more often than studies with non-significant results. Selective reporting: many publications ignored the results of intention to treat analyses and reported the more favourable per protocol analyses only.
Conclusions: The degree of multiple publication, selective publication, and selective reporting differed between products. Thus, any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.
Figures
Similar articles
-
Publication bias in systematic reviews.Arch Gen Psychiatry. 2007 Jul;64(7):868. doi: 10.1001/archpsyc.64.7.868-a. Arch Gen Psychiatry. 2007. PMID: 17606823 No abstract available.
-
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.BMJ. 2010 Oct 12;341:c4737. doi: 10.1136/bmj.c4737. BMJ. 2010. PMID: 20940209 Free PMC article. Review.
-
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.BMJ. 2003 May 31;326(7400):1167-70. doi: 10.1136/bmj.326.7400.1167. BMJ. 2003. PMID: 12775614 Free PMC article. Review.
-
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.Lancet. 2004 Apr 24;363(9418):1341-5. doi: 10.1016/S0140-6736(04)16043-1. Lancet. 2004. PMID: 15110490 Review.
-
Time-lag bias in trials of pediatric antidepressants: a systematic review and meta-analysis.J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):63-72. doi: 10.1016/j.jaac.2010.10.008. Epub 2010 Nov 25. J Am Acad Child Adolesc Psychiatry. 2011. PMID: 21156271 Free PMC article. Review.
Cited by
-
Research Quality of Clinical Trials Reported for Foods with Function Claims in Japan, 2023-2024: Evaluation Based on a Revised Tool to Assess Risk of Bias in Randomized Trials.Nutrients. 2024 Aug 17;16(16):2744. doi: 10.3390/nu16162744. Nutrients. 2024. PMID: 39203880 Free PMC article. Review.
-
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.Cochrane Database Syst Rev. 2024 Jul 3;7(7):CD013425. doi: 10.1002/14651858.CD013425.pub2. Cochrane Database Syst Rev. 2024. PMID: 38958149 Review.
-
Treatment-duration-wise harm profile of insulin-sodium-glucose co-transporter inhibitor co-treatment in type 1 diabetes mellitus patients.J Diabetes Metab Disord. 2023 Feb 15;22(1):673-701. doi: 10.1007/s40200-023-01192-7. eCollection 2023 Jun. J Diabetes Metab Disord. 2023. PMID: 37255836 Free PMC article.
-
Do cash transfers alleviate common mental disorders in low- and middle-income countries? A systematic review and meta-analysis.PLoS One. 2023 Feb 22;18(2):e0281283. doi: 10.1371/journal.pone.0281283. eCollection 2023. PLoS One. 2023. PMID: 36812171 Free PMC article.
-
Deep learning-based quantitative estimation of lymphedema-induced fibrosis using three-dimensional computed tomography images.Sci Rep. 2022 Sep 13;12(1):15371. doi: 10.1038/s41598-022-19204-6. Sci Rep. 2022. PMID: 36100619 Free PMC article.
References
-
- Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263: 1385-9. - PubMed
-
- Dickersin K, Chalmers I. Under-reporting research is scientific misconduct. JAMA 1990;263: 1405-8. - PubMed
-
- Gøtzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol 1989;36: 429-32. - PubMed
-
- Davidoff F, DeAngelis C, Drazen J, Hoet J, Højgaard L, Horton R, et al. Sponsorship, authorship, and accountability [commentary]. Lancet 2001;358: 854-6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources